Chondroitin Sulfate for Osteoarthritis – Is There a Risk for Cancer: an Analysis of Osteoarthritis Initiative Data
Vol. 31 No. 4 (2023), Original Articles
Vol. 31 No. 4 (2023)

Chondroitin Sulfate for Osteoarthritis – Is There a Risk for Cancer: an Analysis of Osteoarthritis Initiative Data

Original Articles
https://doi.org/10.35465/31.4.2023.pp14-27
Published March 11, 2024
Sevdalina Nikolova Lambova
Valery Shirinsky
Ivan Shirinsky
PDF
PDF (Български)

Keywords

osteoarthritis, chondroitin sulfate, cancer

How to Cite

Lambova, S., Shirinsky, V., & Shirinsky, I. (2024). Chondroitin Sulfate for Osteoarthritis – Is There a Risk for Cancer: an Analysis of Osteoarthritis Initiative Data. Rheumatology (Bulgaria), 31(4), 14-27. https://doi.org/10.35465/31.4.2023.pp14-27
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The aim of this study was to evaluate the association between chondroitin   sulfate (CS) use and incidence of self-reported cancer during 6-year follow up in the     publicly available Osteoarthritis Initiative (OAI) cohort participants.

Materials and Methods: The current study included analysis of 6-year longitudinal data obtained from the OAI progression (n= 1390) and incidence (n = 3284) subcohorts that are publicly available at https://nda.nih.gov/oai/. The inclusion criteria for OAI were the following: age between 45 and 79 years for both subcohorts, symptomatic tibiofemoral knee osteoarthritis (OA) for the progression subcohort, and the presence of established or putative risk factors for incident knee OA for the incidence subcohort. The OAI participants were recruited and enrolled between February 2004 and May 2006 at four recruitment centres in the United States. This study received ethical approval from each recruitment centre. All participants provided written informed consent. To reduce the risk of bias, only participants who did not take CS at baseline were included in the analysis (a “new-user” design).

Results: 570 (18%) new users of CS and 2597 (82%) CS non-users were compared. In the CS user group, 294 (51.6%) participants received CS for more than one year, 291 (33.5%) for more than 2 years, 123 (21.6%) for more than 3 years, and 60 (10.5%) for more than 4 years. None of the participants received CS for more than 5 years. CS users and non-users were of the same age, had similar male/female ratio, and similar body mass index. In the non-user group, there were more African-American participants and there were more current smokers. 160 (6.2%) and 37 (6.5%) cases of incident self-reported cancer in the non-users and user groups were identified. There was no association between the use of CS and incident self-reported cancer in the non-adjusted analyses. The adjustments for age, race and smoking status did not change the results.

Conclusion: The results of the current study did not show an association between CS use and self-reported cancers. Considering the complex function of CS in the development and progression of malignant tumors, there is a need for further epidemiological studies evaluating CS effects on specific types of cancers and in different genetic backgrounds.

https://doi.org/10.35465/31.4.2023.pp14-27
PDF
PDF (Български)

References

  1. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019,27(11):1578–89.
  2. Liu X, Eyles J, McLachlan AJ, Mobasheri A. Which supplements can I recommend to my osteoarthritis patients? Rheumatology (Oxford). 2018,57:iv75–87.
  3. Herrero-Beaumont G, Largo R. Osteoarthritis: Chondroitin sulfate - CONCEPT clear, uncertainties unchanged. Nat Rev Rheumatol. 2017,13(10):576–7.
  4. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, et al. EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003,62(12):1145–55.
  5. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther K, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) W. Ann Rheum Dis, 2005,64:669–81.
  6. Kloppenburg M, Kroon FPB, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019,78(1):16–24.
  7. Volpi N, Mantovani V, Galeotti F, Bianchi D, Straniero V, Valoti E, Miraglia N. Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitine Sulfate and Its Constituents in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019,8(3):336-45.
  8. Ronca F, Palmieri L, Panicucci P, Ronca G. (1998). Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 6(Suppl. A), 14–21.
  9. du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther. 2014,142(3):362-74.
  10. Asimakopoulou AP, Theocharis AD, Tzanakakis GN, Karamanos NK. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo. 2008, 22(3):385–9.
  11. Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, et al. The Dietary Supplement chondroitin-4-sulfate exhibits oncogene-specific pro-tumor effects on BRAF V600E melanoma cells. Mol Cell 2018,69(6):923-937.e8.
  12. Pudełko A, Wisowski G, Olczyk K, Koźma EM. The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer. FEBS J. 2019,286(10):1815–37.
  13. Alini M, Losa GA. Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res. 1991, 51(5):1443–8.
  14. Ricciardelli C, Mayne K, Sykes PJ, Raymond, WA, McCaul K, Marshall VR, et al. Elevated progression stromal chondroitin sulfate prostate glycosaminoglycan cancer predicts in early-stage. Clin Cancer Res. 1997,3(6):983–92.
  15. Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, Papageorgakopoulou N, Stavropoulos MS, et al. Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer : Structural and expressional studies. Oncol Rep. 2009, 22(2):369–75.
  16. Weyers A, Yang B, Park J, Kim Y, Kim S, Lee E, et al. Microanalysis of stomach cancer glycosaminoglycans. Glycoconj J. 2013,30(7):701–7.
  17. Pothacharoen P, Siriaunkgul S, Ong-chai S. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem. 2006,140(4):517–24.
  18. Svensson KJ, Christianson HC, Paulina K, Victor F, Lars L, Signe B, et al. Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol. 2011, 39(6):1421–8.
  19. Prinz RD, Willis CM, Viloria-Petit A, Klüppel M. Elimination of breast tumor-associated chondroitin sulfate promotes metastasis. Genet Mol Res. 2011,10(4):3901–13.
  20. Stock C, Jungmann O, Seidler DG. Decorin and chondroitin-6 sulfate Inhibit B16V melanoma cell migration and invasion by cellular acidification. J Cell Physiol. 2011, 226(10):2641–50.
  21. Iida J, Wilhelmson KL, Ng J, Lee P, Morrison C, Tam E, et al. Cell surface chondroitin sulfate glycosaminoglycan in melanoma : role in the activation of pro-MMP-2 ( pro-gelatinase A ). Biochem J. 2007,403(3):553–63.
  22. Willis CM, Klüppel M. Chondroitin Sulfate-E Is a negative regulator of a pro- tumorigenic Wnt / beta-catenin-Collagen 1 axis in breast cancer cells. PLos One. 2014, 9(8): e103966.
  23. Mizumoto S, Watanabe M, Yamada S, Sugahara K. Expression of N -acetylgalactosamine 4-sulfate 6- O -sulfotransferase involved in chondroitin sulfate synthesis is responsible for pulmonary metastasis. Biomed Res Int. 2013,2013:656319.
  24. Vallen MJE, Massuger LFAG, ten Dam GB, Bulten J, van Kuppevelt TH. Gynecologic oncology highly sulfated chondroitin sulfates , a novel class of prognostic biomarkers in ovarian cancer tissue. Gynecol Oncol. 2012,127(1):202–9.
  25. Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, et al. Chondroitin sulfates play a major role in breast cancer metastasis: A role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 2011,13(3):R58.
  26. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998,95(16):9325–30.
  27. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 2008,16(Suppl 3):14–8.
  28. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008,
  29. (1–2):15–30.
  30. Brasky TM, Kristal AR, Lampe JW, White E. Specialty supplements and prostate cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Nutr Cancer. 2012,63(4), 573–82.
  31. Brasky TM, Lampe JW, Potter JD, White E. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiol Biomarkers Prev. 2010, 19(7):1696–708.
  32. Ibáñez-Sanz G, Guinó E, Morros R, Quijada-Manuitt MÁ, de la Peña-Negro LC, Moreno V. Chondroitin Sulphate and Glucosamine Use Depend on Nonsteroidal Anti-inflammatory Drug Use to Modify the Risk for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1809-16.
  33. Ibáñez-Sanz G, Díez-Villanueva A, Vilorio-Marqués L, Gracia E, Aragonés N, Olmedo-
  34. Requena R et al. Possible role of chondroitin sulphate and glucosamine for primary
  35. prevention of colorectal cancer. Results from the MCC-Spain study. Sci
  36. Rep. 2018;8(1):2040.
  37. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J
  38. Epidemiol. 2003;158(9):915-20.
  39. Shirinsky I, Shirinsky V. Chondroitin sulfate use and incidence of cancer: longitudinal
  40. analysis of the Osteoarthritis Initiative Data. Ann Rheum Dis 2019;78:515.
  41. https://nda.nih.gov/oai/.
  42. Pahor M, Chrischilles EA, Guralnik, JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol. 1994,10(4), 405–11.
  43. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in
  44. observational studies. Nat Rev Rheumatol. 2015,11(7):437–41.
  45. Kantor ED, Lampe JW, Peters U, Shen DD, Vaughan TL, White E. Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes Control. 2013, 24(6), 1137–46.
  46. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins And Lifestyle. Cancer Epidemiol Biomarkers Prev. 2009,18(5):1419–28.
  47. Hotaling JM, Wright JL, Pocobelli G, Bhatti P, Porter M, White E. Long-Term Use of Supplemental Vitamins and Minerals Does Not Reduce the Risk of Urothelial Cell Carcinoma of the Bladder in the VITamins And Lifestyle Study. J Urol. 2011,185(4):1210–5.
  48. Walter RB, Brasky TM, Milano F, White E. Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins and lifestyle (VITAL) study. Cancer Epidemiol Biomarkers Prev. 2011,20(10):2298–308.
  49. Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol, . 2012 Feb 15;175(4):250-62.
  50. Navarro C, Chirlaque, MD, Tormo MJ, Pérez-Flores D, Rodríguez-Barranco M, Sánchez-Villegas A, et al. Validity of self reported diagnoses of cancer in a major Spanish prospective cohort study. J Epidemiol Community Health. 2006,60(7):593–9.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.